Targeting LKB1 signaling in cancer

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1835, Issue 2, 2013, Pages 194-210

  Korsse, S E ^a   Peppelenbosch, M P ^a   Van Veelen, W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

LKB1; Metformin; MTOR; Peutz Jeghers syndrome; Rapamycin; Sporadic cancer

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 1 [4 [1 (1,4 DIOXASPIRO[4.5]DEC 8 YL) 4 (8 OXA 3 AZABICYCLO[3.2.1]OCT 3 YL) 1H PYRAZOLO[3,4 D]PYRIMIDIN 6 YL]PHENYL] 3 METHYLUREA; 2 (4 AMINO 1 ISOPROPYL 1H PYRAZOLO[3,4 D]PYRIMIDIN 3 YL) 1H INDOL 5 OL; 2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; 4 (4 AMINO 5 (7 METHOXY 1H INDOL 2 YL)IMIDAZO[5,1 F][1,2,4]TRIAZIN 7 YL)CYCLOHEXANECARBOXYLIC ACID; 6,7 DIHYDRO 4 HYDROXY 3 (2' HYDROXY 1,1' BIPHENYL 4 YL) 6 OXOTHIENO[2,3 B]PYRIDINE 5 CARBONITRILE; ADENYLATE KINASE; ALPHA INTERFERON; AROMATASE INHIBITOR; AZD 8055; BEVACIZUMAB; CISPLATIN; DOXORUBICIN; EVEROLIMUS; GEMCITABINE; GLUCOSE; INSULIN; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; OCTREOTIDE; PACLITAXEL; PLACEBO; PROTEIN KINASE LKB1; RAPAMYCIN; RIDAFOROLIMUS; SOMATOMEDIN C; SORAFENIB; SUNITINIB; TEMSIROLIMUS; UNINDEXED DRUG;

ADJUVANT THERAPY; ANGIOLIPOMA; ANTINEOPLASTIC ACTIVITY; BARRETT ESOPHAGUS; BLADDER CARCINOMA; BREAST CANCER; CANCER RISK; CARCINOGENESIS; CELL ACTIVITY; CELL GROWTH; CELL POLARITY; CELL PROLIFERATION; COLON CANCER; COLON TUMOR; COLORECTAL ADENOMA; COLORECTAL CANCER; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TARGETING; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; ENERGY METABOLISM; ENZYME ACTIVATION; ESOPHAGUS CANCER; GALLBLADDER CANCER; GENE INACTIVATION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GERM LINE; GLUCONEOGENESIS; HAMARTOMA; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; INSULIN SENSITIVITY; INTESTINE CANCER; INTESTINE POLYP; KIDNEY ADENOMA; KIDNEY CARCINOMA; KIDNEY HEMANGIOMYOLIPOMA; LIVER ANGIOLIPOMA; LIVER HEMANGIOMA; LKB1 GENE; LUNG CANCER; LUNG NON SMALL CELL CANCER; LYMPHANGIOLEIOMYOMATOSIS; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MULTICENTER STUDY (TOPIC); NERVE SHEATH TUMOR; NEUROECTODERM TUMOR; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OVARY CANCER; OVARY POLYCYSTIC DISEASE; OVERALL SURVIVAL; PANCREAS CANCER; PEUTZ JEGHERS SYNDROME; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHEOCHROMOCYTOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR DOWN REGULATION; REVIEW; SIGNAL TRANSDUCTION; STOMACH CANCER; SUBEPENDYMAL GIANT CELL ASTROCYTOMA; THYROID FOLLICULAR CARCINOMA; TUMOR SUPPRESSOR GENE; UNSPECIFIED SIDE EFFECT;

ANIMALS; CELL POLARITY; HUMANS; METFORMIN; NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84873167692     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2012.12.006     Document Type: Review

References (339)

1. Peutz J.L.A. Over een zeer merkwaardige, gecombineerde familiaire polyposis van de slijmvliezen van den tractus intestinalis met die van de neuskeelholte en gepaard met eigenaardige pigmentaties van huid en slijmvliezen. Ned. Maandschr. v. Geneesk. 1921, 10:134-146.
2. Jeghers H., Mc K.V., Katz K.H. Generalized intestinal polyposis and melanin spots of the oral mucosa, lips and digits; a syndrome of diagnostic significance. N. Engl. J. Med. 1949, 241:1031-1036.
3. Lindor N.M., McMaster M.L., Lindor C.J., Greene M.H. Concise handbook of familial cancer susceptibility syndromes - second edition. J. Natl. Cancer Inst. Monogr. 2008, 1-93.
4. Bosman F.T., Carneiro F., Hruban R.H., Theise N.D. WHO Classification of Tumours of the Digestive System 2010, vol. 3:417. IARC Press, Lyon.
5. Latchford A.R., Neale K., Phillips R.K., Clark S.K. Peutz-Jeghers syndrome: intriguing suggestion of gastrointestinal cancer prevention from surveillance. Dis. Colon Rectum 2011, 54:1547-1551.
6. Hizawa K., Iida M., Matsumoto T., Kohrogi N., Yao T., Fujishima M. Neoplastic transformation arising in Peutz-Jeghers polyposis. Dis. Colon Rectum 1993, 36:953-957.
7. Entius M.M., Westerman A.M., Giardiello F.M., van Velthuysen M.L., Polak M.M., Slebos R.J., Wilson J.H., Hamilton S.R., Offerhaus G.J. Peutz-Jeghers polyps, dysplasia, and K-ras codon 12 mutations. Gut 1997, 41:320-322.
8. Tomlinson I.P., Houlston R.S. Peutz-Jeghers syndrome. J. Med. Genet. 1997, 34:1007-1011.
9. van Lier M.G., Mathus-Vliegen E.M., Wagner A., van Leerdam M.E., Kuipers E.J. High cumulative risk of intussusception in patients with Peutz-Jeghers syndrome: time to update surveillance guidelines?. Am. J. Gastroenterol. 2011, 106:940-945.
10. van Lier M.G., Wagner A., Mathus-Vliegen E.M., Kuipers E.J., Steyerberg E.W., van Leerdam M.E. High cancer risk in Peutz-Jeghers syndrome: a systematic review and surveillance recommendations. Am. J. Gastroenterol. 2010, 105:1258-1264. (author reply 1265).
11. van Lier M.G., Westerman A.M., Wagner A., Looman C.W., Wilson J.H., de Rooij F.W., Lemmens V.E., Kuipers E.J., Mathus-Vliegen E.M., van Leerdam M.E. High cancer risk and increased mortality in patients with Peutz-Jeghers syndrome. Gut 2011, 60:141-147.
12. Giardiello F.M., Welsh S.B., Hamilton S.R., Offerhaus G.J., Gittelsohn A.M., Booker S.V., Krush A.J., Yardley J.H., Luk G.D. Increased risk of cancer in the Peutz-Jeghers syndrome. N. Engl. J. Med. 1987, 316:1511-1514.
13. Hemminki A., Tomlinson I., Markie D., Jarvinen H., Sistonen P., Bjorkqvist A.M., Knuutila S., Salovaara R., Bodmer W., Shibata D., de la Chapelle A., Aaltonen L.A. Localization of a susceptibility locus for Peutz-Jeghers syndrome to 19p using comparative genomic hybridization and targeted linkage analysis. Nat. Genet. 1997, 15:87-90.
14. Hemminki A., Markie D., Tomlinson I., Avizienyte E., Roth S., Loukola A., Bignell G., Warren W., Aminoff M., Hoglund P., Jarvinen H., Kristo P., Pelin K., Ridanpaa M., Salovaara R., Toro T., Bodmer W., Olschwang S., Olsen A.S., Stratton M.R., de la Chapelle A., Aaltonen L.A. A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature 1998, 391:184-187.
15. Jenne D.E., Reimann H., Nezu J., Friedel W., Loff S., Jeschke R., Muller O., Back W., Zimmer M. Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nat. Genet. 1998, 18:38-43.
16. Amos C.I., Keitheri-Cheteri M.B., Sabripour M., Wei C., McGarrity T.J., Seldin M.F., Nations L., Lynch P.M., Fidder H.H., Friedman E., Frazier M.L. Genotype-phenotype correlations in Peutz-Jeghers syndrome. J. Med. Genet. 2004, 41:327-333.
17. Ylikorkala A., Rossi D.J., Korsisaari N., Luukko K., Alitalo K., Henkemeyer M., Makela T.P. Vascular abnormalities and deregulation of VEGF in Lkb1-deficient mice. Science 2001, 293:1323-1326.
18. Bardeesy N., Sinha M., Hezel A.F., Signoretti S., Hathaway N.A., Sharpless N.E., Loda M., Carrasco D.R., DePinho R.A. Loss of the Lkb1 tumour suppressor provokes intestinal polyposis but resistance to transformation. Nature 2002, 419:162-167.
19. Miyoshi H., Nakau M., Ishikawa T.O., Seldin M.F., Oshima M., Taketo M.M. Gastrointestinal hamartomatous polyposis in Lkb1 heterozygous knockout mice. Cancer Res. 2002, 62:2261-2266.
20. Entius M.M., Keller J.J., Westerman A.M., van Rees B.P., van Velthuysen M.L., de Goeij A.F., Wilson J.H., Giardiello F.M., Offerhaus G.J. Molecular genetic alterations in hamartomatous polyps and carcinomas of patients with Peutz-Jeghers syndrome. J. Clin. Pathol. 2001, 54:126-131.
21. Gruber S.B., Entius M.M., Petersen G.M., Laken S.J., Longo P.A., Boyer R., Levin A.M., Mujumdar U.J., Trent J.M., Kinzler K.W., Vogelstein B., Hamilton S.R., Polymeropoulos M.H., Offerhaus G.J., Giardiello F.M. Pathogenesis of adenocarcinoma in Peutz-Jeghers syndrome. Cancer Res. 1998, 58:5267-5270.
22. Jishage K., Nezu J., Kawase Y., Iwata T., Watanabe M., Miyoshi A., Ose A., Habu K., Kake T., Kamada N., Ueda O., Kinoshita M., Jenne D.E., Shimane M., Suzuki H. Role of Lkb1, the causative gene of Peutz-Jegher's syndrome, in embryogenesis and polyposis. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:8903-8908.
23. Huang X., Wullschleger S., Shpiro N., McGuire V.A., Sakamoto K., Woods Y.L., McBurnie W., Fleming S., Alessi D.R. Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice. Biochem. J. 2008, 412:211-221.
24. Morton J.P., Jamieson N.B., Karim S.A., Athineos D., Ridgway R.A., Nixon C., McKay C.J., Carter R., Brunton V.G., Frame M.C., Ashworth A., Oien K.A., Evans T.R., Sansom O.J. LKB1 haploinsufficiency cooperates with Kras to promote pancreatic cancer through suppression of p21-dependent growth arrest. Gastroenterology 2010, 139:586-597. (597 e581-586).
25. -/- compound mutant mice. Oncogene 2006, 25:1816-1820.
26. Wei C., Amos C.I., Stephens L.C., Campos I., Deng J.M., Behringer R.R., Rashid A., Frazier M.L. Mutation of Lkb1 and p53 genes exert a cooperative effect on tumorigenesis. Cancer Res. 2005, 65:11297-11303.
27. Katajisto P., Vaahtomeri K., Ekman N., Ventela E., Ristimaki A., Bardeesy N., Feil R., DePinho R.A., Makela T.P. LKB1 signaling in mesenchymal cells required for suppression of gastrointestinal polyposis. Nat. Genet. 2008, 40:455-459.
28. Moren A., Raja E., Heldin C.H., Moustakas A. Negative regulation of TGFbeta signaling by the kinase LKB1 and the scaffolding protein LIP1. J. Biol. Chem. 2011, 286:341-353.
29. Herrmann J.L., Byekova Y., Elmets C.A., Athar M. Liver kinase B1 (LKB1) in the pathogenesis of epithelial cancers. Cancer Lett. 2011, 306:1-9.
30. Sanchez-Cespedes M. A role for LKB1 gene in human cancer beyond the Peutz-Jeghers syndrome. Oncogene 2007, 26:7825-7832.
31. Dong S.M., Kim K.M., Kim S.Y., Shin M.S., Na E.Y., Lee S.H., Park W.S., Yoo N.J., Jang J.J., Yoon C.Y., Kim J.W., Yang Y.M., Kim S.H., Kim C.S., Lee J.Y. Frequent somatic mutations in serine/threonine kinase 11/Peutz-Jeghers syndrome gene in left-sided colon cancer. Cancer Res. 1998, 58:3787-3790.
32. Launonen V., Avizienyte E., Loukola A., Laiho P., Salovaara R., Jarvinen H., Mecklin J.P., Oku A., Shimane M., Kim H.C., Kim J.C., Nezu J., Aaltonen L.A. No evidence of Peutz-Jeghers syndrome gene LKB1 involvement in left-sided colorectal carcinomas. Cancer Res. 2000, 60:546-548.
33. Sahin F., Maitra A., Argani P., Sato N., Maehara N., Montgomery E., Goggins M., Hruban R.H., Su G.H. Loss of Stk11/Lkb1 expression in pancreatic and biliary neoplasms. Mod. Pathol. 2003, 16:686-691.
34. Qanungo S., Haldar S., Basu A. Restoration of silenced Peutz-Jeghers syndrome gene, LKB1, induces apoptosis in pancreatic carcinoma cells. Neoplasia 2003, 5:367-374.
35. Hezel A.F., Gurumurthy S., Granot Z., Swisa A., Chu G.C., Bailey G., Dor Y., Bardeesy N., Depinho R.A. Pancreatic LKB1 deletion leads to acinar polarity defects and cystic neoplasms. Mol. Cell. Biol. 2008, 28:2414-2425.
36. Fenton H., Carlile B., Montgomery E.A., Carraway H., Herman J., Sahin F., Su G.H., Argani P. LKB1 protein expression in human breast cancer. Appl. Immunohistochem. Mol. Morphol. 2006, 14:146-153.
37. Shen Z., Wen X.F., Lan F., Shen Z.Z., Shao Z.M. The tumor suppressor gene LKB1 is associated with prognosis in human breast carcinoma. Clin. Cancer Res. 2002, 8:2085-2090.
38. Yang T.L., Su Y.R., Huang C.S., Yu J.C., Lo Y.L., Wu P.E., Shen C.Y. High-resolution 19p13.2-13.3 allelotyping of breast carcinomas demonstrates frequent loss of heterozygosity. Genes Chromosom. Cancer 2004, 41:250-256.
39. Taliaferro-Smith L., Nagalingam A., Zhong D., Zhou W., Saxena N.K., Sharma D. LKB1 is required for adiponectin-mediated modulation of AMPK-S6K axis and inhibition of migration and invasion of breast cancer cells. Oncogene 2009, 28:2621-2633.
40. Zhuang Z.G., Di G.H., Shen Z.Z., Ding J., Shao Z.M. Enhanced expression of LKB1 in breast cancer cells attenuates angiogenesis, invasion, and metastatic potential. Mol. Cancer Res. 2006, 4:843-849.
41. Launonen V. Mutations in the human LKB1/STK11 gene. Hum. Mutat. 2005, 26:291-297.
42. Gao Y., Ge G., Ji H. LKB1 in lung cancerigenesis: a serine/threonine kinase as tumor suppressor. Protein Cell 2011, 2:99-107.
43. Matsumoto S., Iwakawa R., Takahashi K., Kohno T., Nakanishi Y., Matsuno Y., Suzuki K., Nakamoto M., Shimizu E., Minna J.D., Yokota J. Prevalence and specificity of LKB1 genetic alterations in lung cancers. Oncogene 2007, 26:5911-5918.
44. Onozato R., Kosaka T., Achiwa H., Kuwano H., Takahashi T., Yatabe Y., Mitsudomi T. LKB1 gene mutations in Japanese lung cancer patients. Cancer Sci. 2007, 98:1747-1751.
45. Ji H., Ramsey M.R., Hayes D.N., Fan C., McNamara K., Kozlowski P., Torrice C., Wu M.C., Shimamura T., Perera S.A., Liang M.C., Cai D., Naumov G.N., Bao L., Contreras C.M., Li D., Chen L., Krishnamurthy J., Koivunen J., Chirieac L.R., Padera R.F., Bronson R.T., Lindeman N.I., Christiani D.C., Lin X., Shapiro G.I., Janne P.A., Johnson B.E., Meyerson M., Kwiatkowski D.J., Castrillon D.H., Bardeesy N., Sharpless N.E., Wong K.K. LKB1 modulates lung cancer differentiation and metastasis. Nature 2007, 448:807-810.
46. Avizienyte E., Roth S., Loukola A., Hemminki A., Lothe R.A., Stenwig A.E., Fossa S.D., Salovaara R., Aaltonen L.A. Somatic mutations in LKB1 are rare in sporadic colorectal and testicular tumors. Cancer Res. 1998, 58:2087-2090.
47. Wang Z.J., Taylor F., Churchman M., Norbury G., Tomlinson I. Genetic pathways of colorectal carcinogenesis rarely involve the PTEN and LKB1 genes outside the inherited hamartoma syndromes. Am. J. Pathol. 1998, 153:363-366.
48. Resta N., Simone C., Mareni C., Montera M., Gentile M., Susca F., Gristina R., Pozzi S., Bertario L., Bufo P., Carlomagno N., Ingrosso M., Rossini F.P., Tenconi R., Guanti G. STK11 mutations in Peutz-Jeghers syndrome and sporadic colon cancer. Cancer Res. 1998, 58:4799-4801.
49. Nakagawa H., Koyama K., Nakamori S., Kameyama M., Imaoka S., Monden M., Nakamura Y. Frameshift mutation of the STK11 gene in a sporadic gastrointestinal cancer with microsatellite instability. Jpn. J. Cancer Res. 1999, 90:633-637.
50. Trojan J., Brieger A., Raedle J., Esteller M., Zeuzem S. 5'-CpG island methylation of the LKB1/STK11 promoter and allelic loss at chromosome 19p13.3 in sporadic colorectal cancer. Gut 2000, 47:272-276.
51. Forster L.F., Defres S., Goudie D.R., Baty D.U., Carey F.A. An investigation of the Peutz-Jeghers gene (LKB1) in sporadic breast and colon cancers. J. Clin. Pathol. 2000, 53:791-793.
52. Sobottka S.B., Haase M., Fitze G., Hahn M., Schackert H.K., Schackert G. Frequent loss of heterozygosity at the 19p13.3 locus without LKB1/STK11 mutations in human carcinoma metastases to the brain. J. Neurooncol. 2000, 49:187-195.
53. Park W.S., Moon Y.W., Yang Y.M., Kim Y.S., Kim Y.D., Fuller B.G., Vortmeyer A.O., Fogt F., Lubensky I.A., Zhuang Z. Mutations of the STK11 gene in sporadic gastric carcinoma. Int. J. Oncol. 1998, 13:601-604.
54. Avizienyte E., Loukola A., Roth S., Hemminki A., Tarkkanen M., Salovaara R., Arola J., Butzow R., Husgafvel-Pursiainen K., Kokkola A., Jarvinen H., Aaltonen L.A. LKB1 somatic mutations in sporadic tumors. Am. J. Pathol. 1999, 154:677-681.
55. Su G.H., Hruban R.H., Bansal R.K., Bova G.S., Tang D.J., Shekher M.C., Westerman A.M., Entius M.M., Goggins M., Yeo C.J., Kern S.E. Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers. Am. J. Pathol. 1999, 154:1835-1840.
56. Sato N., Rosty C., Jansen M., Fukushima N., Ueki T., Yeo C.J., Cameron J.L., Iacobuzio-Donahue C.A., Hruban R.H., Goggins M. STK11/LKB1 Peutz-Jeghers gene inactivation in intraductal papillary-mucinous neoplasms of the pancreas. Am. J. Pathol. 2001, 159:2017-2022.
57. de Wilde R.F., Ottenhof N.A., Jansen M., Morsink F.H., de Leng W.W., Offerhaus G.J., Brosens L.A. Analysis of LKB1 mutations and other molecular alterations in pancreatic acinar cell carcinoma. Mod. Pathol. 2011, 24:1229-1236.
58. Bignell G.R., Barfoot R., Seal S., Collins N., Warren W., Stratton M.R. Low frequency of somatic mutations in the LKB1/Peutz-Jeghers syndrome gene in sporadic breast cancer. Cancer Res. 1998, 58:1384-1386.
59. Wang Z.J., Churchman M., Campbell I.G., Xu W.H., Yan Z.Y., McCluggage W.G., Foulkes W.D., Tomlinson I.P. Allele loss and mutation screen at the Peutz-Jeghers (LKB1) locus (19p13.3) in sporadic ovarian tumours. Br. J. Cancer 1999, 80:70-72.
60. Connolly D.C., Katabuchi H., Cliby W.A., Cho K.R. Somatic mutations in the STK11/LKB1 gene are uncommon in rare gynecological tumor types associated with Peutz-Jegher's syndrome. Am. J. Pathol. 2000, 156:339-345.
61. Kato N., Romero M., Catasus L., Prat J. The STK11/LKB1 Peutz-Jegher gene is not involved in the pathogenesis of sporadic sex cord-stromal tumors, although loss of heterozygosity at 19p13.3 indicates other gene alteration in these tumors. Hum. Pathol. 2004, 35:1101-1104.
62. Sanchez-Cespedes M., Parrella P., Esteller M., Nomoto S., Trink B., Engles J.M., Westra W.H., Herman J.G., Sidransky D. Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. Cancer Res. 2002, 62:3659-3662.
63. Koivunen J.P., Kim J., Lee J., Rogers A.M., Park J.O., Zhao X., Naoki K., Okamoto I., Nakagawa K., Yeap B.Y., Meyerson M., Wong K.K., Richards W.G., Sugarbaker D.J., Johnson B.E., Janne P.A. Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients. Br. J. Cancer 2008, 99:245-252.
64. Strazisar M., Mlakar V., Rott T., Glavac D. Somatic alterations of the serine/threonine kinase LKB1 gene in squamous cell (SCC) and large cell (LCC) lung carcinoma. Cancer Investig. 2009, 27:407-416.
65. Osoegawa A., Kometani T., Nosaki K., Ondo K., Hamatake M., Hirai F., Seto T., Sugio K., Ichinose Y. LKB1 mutations frequently detected in mucinous bronchioloalveolar carcinoma. Jpn. J. Clin. Oncol. 2011, 41:1132-1137.
66. Rowan A., Bataille V., MacKie R., Healy E., Bicknell D., Bodmer W., Tomlinson I. Somatic mutations in the Peutz-Jeghers (LKB1/STKII) gene in sporadic malignant melanomas. J. Investig. Dermatol. 1999, 112:509-511.
67. Guldberg P., thor Straten P., Ahrenkiel V., Seremet T., Kirkin A.F., Zeuthen J. Somatic mutation of the Peutz-Jeghers syndrome gene, LKB1/STK11, in malignant melanoma. Oncogene 1999, 18:1777-1780.
68. Boudeau J., Baas A.F., Deak M., Morrice N.A., Kieloch A., Schutkowski M., Prescott A.R., Clevers H.C., Alessi D.R. MO25alpha/beta interact with STRADalpha/beta enhancing their ability to bind, activate and localize LKB1 in the cytoplasm. EMBO J. 2003, 22:5102-5114.
69. Mehenni H., Gehrig C., Nezu J., Oku A., Shimane M., Rossier C., Guex N., Blouin J.L., Scott H.S., Antonarakis S.E. Loss of LKB1 kinase activity in Peutz-Jeghers syndrome, and evidence for allelic and locus heterogeneity. Am. J. Hum. Genet. 1998, 63:1641-1650.
70. Ylikorkala A., Avizienyte E., Tomlinson I.P., Tiainen M., Roth S., Loukola A., Hemminki A., Johansson M., Sistonen P., Markie D., Neale K., Phillips R., Zauber P., Twama T., Sampson J., Jarvinen H., Makela T.P., Aaltonen L.A. Mutations and impaired function of LKB1 in familial and non-familial Peutz-Jeghers syndrome and a sporadic testicular cancer. Hum. Mol. Genet. 1999, 8:45-51.
71. Forcet C., Etienne-Manneville S., Gaude H., Fournier L., Debilly S., Salmi M., Baas A., Olschwang S., Clevers H., Billaud M. Functional analysis of Peutz-Jeghers mutations reveals that the LKB1 C-terminal region exerts a crucial role in regulating both the AMPK pathway and the cell polarity. Hum. Mol. Genet. 2005, 14:1283-1292.
72. Baas A.F., Boudeau J., Sapkota G.P., Smit L., Medema R., Morrice N.A., Alessi D.R., Clevers H.C. Activation of the tumour suppressor kinase LKB1 by the STE20-like pseudokinase STRAD. EMBO J. 2003, 22:3062-3072.
73. Sapkota G.P., Boudeau J., Deak M., Kieloch A., Morrice N., Alessi D.R. Identification and characterization of four novel phosphorylation sites (Ser31, Ser325, Thr336 and Thr366) on LKB1/STK11, the protein kinase mutated in Peutz-Jeghers cancer syndrome. Biochem. J. 2002, 362:481-490.
74. Sapkota G.P., Kieloch A., Lizcano J.M., Lain S., Arthur J.S., Williams M.R., Morrice N., Deak M., Alessi D.R. Phosphorylation of the protein kinase mutated in Peutz-Jeghers cancer syndrome, LKB1/STK11, at Ser431 by p90(RSK) and cAMP-dependent protein kinase, but not its farnesylation at Cys(433), is essential for LKB1 to suppress cell growth. J. Biol. Chem. 2001, 276:19469-19482.
75. Collins S.P., Reoma J.L., Gamm D.M., Uhler M.D. LKB1, a novel serine/threonine protein kinase and potential tumour suppressor, is phosphorylated by cAMP-dependent protein kinase (PKA) and prenylated in vivo. Biochem. J. 2000, 345(Pt 3):673-680.
76. Sapkota G.P., Deak M., Kieloch A., Morrice N., Goodarzi A.A., Smythe C., Shiloh Y., Lees-Miller S.P., Alessi D.R. Ionizing radiation induces ataxia telangiectasia mutated kinase (ATM)-mediated phosphorylation of LKB1/STK11 at Thr-366. Biochem. J. 2002, 368:507-516.
77. Song P., Xie Z., Wu Y., Xu J., Dong Y., Zou M.H. Protein kinase Czeta-dependent LKB1 serine 428 phosphorylation increases LKB1 nucleus export and apoptosis in endothelial cells. J. Biol. Chem. 2008, 283:12446-12455.
78. Smith D.P., Spicer J., Smith A., Swift S., Ashworth A. The mouse Peutz-Jeghers syndrome gene Lkb1 encodes a nuclear protein kinase. Hum. Mol. Genet. 1999, 8:1479-1485.
79. Hawley S.A., Boudeau J., Reid J.L., Mustard K.J., Udd L., Makela T.P., Alessi D.R., Hardie D.G. Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. J. Biol. 2003, 2:28.
80. Jaleel M., McBride A., Lizcano J.M., Deak M., Toth R., Morrice N.A., Alessi D.R. Identification of the sucrose non-fermenting related kinase SNRK, as a novel LKB1 substrate. FEBS Lett. 2005, 579:1417-1423.
81. Lizcano J.M., Goransson O., Toth R., Deak M., Morrice N.A., Boudeau J., Hawley S.A., Udd L., Makela T.P., Hardie D.G., Alessi D.R. LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1. EMBO J. 2004, 23:833-843.
82. Martin S.G., St Johnston D. A role for Drosophila LKB1 in anterior-posterior axis formation and epithelial polarity. Nature 2003, 421:379-384.
83. Watts J.L., Morton D.G., Bestman J., Kemphues K.J. The C. elegans par-4 gene encodes a putative serine-threonine kinase required for establishing embryonic asymmetry. Development 2000, 127:1467-1475.
84. Baas A.F., Kuipers J., van der Wel N.N., Batlle E., Koerten H.K., Peters P.J., Clevers H.C. Complete polarization of single intestinal epithelial cells upon activation of LKB1 by STRAD. Cell 2004, 116:457-466.
85. Cowan C.R., Hyman A.A. Acto-myosin reorganization and PAR polarity in C. elegans. Development 2007, 134:1035-1043.
86. Lee J.H., Koh H., Kim M., Kim Y., Lee S.Y., Karess R.E., Lee S.H., Shong M., Kim J.M., Kim J., Chung J. Energy-dependent regulation of cell structure by AMP-activated protein kinase. Nature 2007, 447:1017-1020.
87. Zhang L., Li J., Young L.H., Caplan M.J. AMP-activated protein kinase regulates the assembly of epithelial tight junctions. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:17272-17277.
88. Zhang S., Schafer-Hales K., Khuri F.R., Zhou W., Vertino P.M., Marcus A.I. The tumor suppressor LKB1 regulates lung cancer cell polarity by mediating cdc42 recruitment and activity. Cancer Res. 2008, 68:740-748.
89. Zheng B., Cantley L.C. Regulation of epithelial tight junction assembly and disassembly by AMP-activated protein kinase. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:819-822.
90. Drewes G., Ebneth A., Mandelkow E.M. MAPs, MARKs and microtubule dynamics. Trends Biochem. Sci. 1998, 23:307-311.
91. Kojima Y., Miyoshi H., Clevers H.C., Oshima M., Aoki M., Taketo M.M. Suppression of tubulin polymerization by the LKB1-microtubule-associated protein/microtubule affinity-regulating kinase signaling. J. Biol. Chem. 2007, 282:23532-23540.
92. Barnes A.P., Lilley B.N., Pan Y.A., Plummer L.J., Powell A.W., Raines A.N., Sanes J.R., Polleux F. LKB1 and SAD kinases define a pathway required for the polarization of cortical neurons. Cell 2007, 129:549-563.
93. Kishi M., Pan Y.A., Crump J.G., Sanes J.R. Mammalian SAD kinases are required for neuronal polarization. Science 2005, 307:929-932.
94. Betschinger J., Knoblich J.A. Dare to be different: asymmetric cell division in Drosophila, C. elegans and vertebrates. Curr. Biol. 2004, 14:R674-R685.
95. Boehlke C., Kotsis F., Patel V., Braeg S., Voelker H., Bredt S., Beyer T., Janusch H., Hamann C., Godel M., Muller K., Herbst M., Hornung M., Doerken M., Kottgen M., Nitschke R., Igarashi P., Walz G., Kuehn E.W. Primary cilia regulate mTORC1 activity and cell size through Lkb1. Nat. Cell Biol. 2010, 12:1115-1122.
96. Gloerich M., ten Klooster J.P., Vliem M.J., Koorman T., Zwartkruis F.J., Clevers H., Bos J.L. Rap2A links intestinal cell polarity to brush border formation. Nat. Cell Biol. 2012, 14:793-801.
97. Rodriguez-Fraticelli A.E., Auzan M., Alonso M.A., Bornens M., Martin-Belmonte F. Cell confinement controls centrosome positioning and lumen initiation during epithelial morphogenesis. J. Cell Biol. 2012, 198:1011-1023.
98. Ossipova O., Bardeesy N., DePinho R.A., Green J.B. LKB1 (XEEK1) regulates Wnt signalling in vertebrate development. Nat. Cell Biol. 2003, 5:889-894.
99. Martin-Belmonte F., Perez-Moreno M. Epithelial cell polarity, stem cells and cancer. Nat. Rev. Cancer 2012, 12:23-38.
100. Jansen M., Ten Klooster J.P., Offerhaus G.J., Clevers H. LKB1 and AMPK family signaling: the intimate link between cell polarity and energy metabolism. Physiol. Rev. 2009, 89:777-798.
101. McCaffrey L.M., Macara I.G. Epithelial organization, cell polarity and tumorigenesis. Trends Cell Biol. 2011, 21:727-735.
102. Corton J.M., Gillespie J.G., Hardie D.G. Role of the AMP-activated protein kinase in the cellular stress response. Curr. Biol. 1994, 4:315-324.
103. Hardie D.G. Minireview: the AMP-activated protein kinase cascade: the key sensor of cellular energy status. Endocrinology 2003, 144:5179-5183.
104. Woods A., Cheung P.C., Smith F.C., Davison M.D., Scott J., Beri R.K., Carling D. Characterization of AMP-activated protein kinase beta and gamma subunits. Assembly of the heterotrimeric complex in vitro. J. Biol. Chem. 1996, 271:10282-10290.
105. Hawley S.A., Davison M., Woods A., Davies S.P., Beri R.K., Carling D., Hardie D.G. Characterization of the AMP-activated protein kinase from rat liver and identification of threonine 172 as the major site at which it phosphorylates AMP-activated protein kinase. J. Biol. Chem. 1996, 271:27879-27887.
106. Hong S.P., Leiper F.C., Woods A., Carling D., Carlson M. Activation of yeast Snf1 and mammalian AMP-activated protein kinase by upstream kinases. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:8839-8843.
107. Shaw R.J., Kosmatka M., Bardeesy N., Hurley R.L., Witters L.A., DePinho R.A., Cantley L.C. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:3329-3335.
108. Carling D., Clarke P.R., Zammit V.A., Hardie D.G. Purification and characterization of the AMP-activated protein kinase. Copurification of acetyl-CoA carboxylase kinase and 3-hydroxy-3-methylglutaryl-CoA reductase kinase activities. Eur. J. Biochem. 1989, 186:129-136.
109. Carling D., Hardie D.G. The substrate and sequence specificity of the AMP-activated protein kinase. Phosphorylation of glycogen synthase and phosphorylase kinase. Biochim. Biophys. Acta 1989, 1012:81-86.
110. Sim A.T., Hardie D.G. The low activity of acetyl-CoA carboxylase in basal and glucagon-stimulated hepatocytes is due to phosphorylation by the AMP-activated protein kinase and not cyclic AMP-dependent protein kinase. FEBS Lett. 1988, 233:294-298.
111. Shaw R.J., Bardeesy N., Manning B.D., Lopez L., Kosmatka M., DePinho R.A., Cantley L.C. The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 2004, 6:91-99.
112. Inoki K., Zhu T., Guan K.L. TSC2 mediates cellular energy response to control cell growth and survival. Cell 2003, 115:577-590.
113. Zhang Y., Gao X., Saucedo L.J., Ru B., Edgar B.A., Pan D. Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat. Cell Biol. 2003, 5:578-581.
114. Gwinn D.M., Shackelford D.B., Egan D.F., Mihaylova M.M., Mery A., Vasquez D.S., Turk B.E., Shaw R.J. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol. Cell 2008, 30:214-226.
115. Hara K., Yonezawa K., Kozlowski M.T., Sugimoto T., Andrabi K., Weng Q.P., Kasuga M., Nishimoto I., Avruch J. Regulation of eIF-4E BP1 phosphorylation by mTOR. J. Biol. Chem. 1997, 272:26457-26463.
116. Hudson C.C., Liu M., Chiang G.G., Otterness D.M., Loomis D.C., Kaper F., Giaccia A.J., Abraham R.T. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol. Cell. Biol. 2002, 22:7004-7014.
117. Hosokawa N., Hara T., Kaizuka T., Kishi C., Takamura A., Miura Y., Iemura S., Natsume T., Takehana K., Yamada N., Guan J.L., Oshiro N., Mizushima N. Nutrient-dependent mTORC1 association with the ULK1-Atg13-FIP200 complex required for autophagy. Mol. Biol. Cell 2009, 20:1981-1991.
118. Jung C.H., Jun C.B., Ro S.H., Kim Y.M., Otto N.M., Cao J., Kundu M., Kim D.H. ULK-Atg13-FIP200 complexes mediate mTOR signaling to the autophagy machinery. Mol. Biol. Cell 2009, 20:1992-2003.
119. Gan B., Hu J., Jiang S., Liu Y., Sahin E., Zhuang L., Fletcher-Sananikone E., Colla S., Wang Y.A., Chin L., Depinho R.A. Lkb1 regulates quiescence and metabolic homeostasis of haematopoietic stem cells. Nature 2010, 468:701-704.
120. Gurumurthy S., Xie S.Z., Alagesan B., Kim J., Yusuf R.Z., Saez B., Tzatsos A., Ozsolak F., Milos P., Ferrari F., Park P.J., Shirihai O.S., Scadden D.T., Bardeesy N. The Lkb1 metabolic sensor maintains haematopoietic stem cell survival. Nature 2010, 468:659-663.
121. Nakada D., Saunders T.L., Morrison S.J. Lkb1 regulates cell cycle and energy metabolism in haematopoietic stem cells. Nature 2010, 468:653-658.
122. Zeng P.Y., Berger S.L. LKB1 is recruited to the p21/WAF1 promoter by p53 to mediate transcriptional activation. Cancer Res. 2006, 66:10701-10708.
123. Tiainen M., Vaahtomeri K., Ylikorkala A., Makela T.P. Growth arrest by the LKB1 tumor suppressor: induction of p21(WAF1/CIP1). Hum. Mol. Genet. 2002, 11:1497-1504.
124. Jimenez A.I., Fernandez P., Dominguez O., Dopazo A., Sanchez-Cespedes M. Growth and molecular profile of lung cancer cells expressing ectopic LKB1: down-regulation of the phosphatidylinositol 3'-phosphate kinase/PTEN pathway. Cancer Res. 2003, 63:1382-1388.
125. Xie X., Wang Z., Chen Y. Association of LKB1 with a WD-repeat protein WDR6 is implicated in cell growth arrest and p27(Kip1) induction. Mol. Cell. Biochem. 2007, 301:115-122.
126. Gurumurthy S., Hezel A.F., Sahin E., Berger J.H., Bosenberg M.W., Bardeesy N. LKB1 deficiency sensitizes mice to carcinogen-induced tumorigenesis. Cancer Res. 2008, 68:55-63.
127. Scott K.D., Nath-Sain S., Agnew M.D., Marignani P.A. LKB1 catalytically deficient mutants enhance cyclin D1 expression. Cancer Res. 2007, 67:5622-5627.
128. Liang X., Wang P., Gao Q., Xiang T., Tao X. Endogenous LKB1 knockdown accelerates G(1)/S transition through p53 and p16 pathways. Cancer Biol. Ther. 2010, 9:156-160.
129. Setogawa T., Shinozaki-Yabana S., Masuda T., Matsuura K., Akiyama T. The tumor suppressor LKB1 induces p21 expression in collaboration with LMO4, GATA-6, and Ldb1. Biochem. Biophys. Res. Commun. 2006, 343:1186-1190.
130. Liang J., Shao S.H., Xu Z.X., Hennessy B., Ding Z., Larrea M., Kondo S., Dumont D.J., Gutterman J.U., Walker C.L., Slingerland J.M., Mills G.B. The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis. Nat. Cell Biol. 2007, 9:218-224.
131. Cheng H., Liu P., Wang Z.C., Zou L., Santiago S., Garbitt V., Gjoerup O.V., Iglehart J.D., Miron A., Richardson A.L., Hahn W.C., Zhao J.J. SIK1 couples LKB1 to p53-dependent anoikis and suppresses metastasis. Sci. Signal. 2009, 2:ra35.
132. Karuman P., Gozani O., Odze R.D., Zhou X.C., Zhu H., Shaw R., Brien T.P., Bozzuto C.D., Ooi D., Cantley L.C., Yuan J. The Peutz-Jegher gene product LKB1 is a mediator of p53-dependent cell death. Mol. Cell 2001, 7:1307-1319.
133. Lee J.H., Koh H., Kim M., Park J., Lee S.Y., Lee S., Chung J. JNK pathway mediates apoptotic cell death induced by tumor suppressor LKB1 in Drosophila. Cell Death Differ. 2006, 13:1110-1122.
134. Deepa S.S., Zhou L., Ryu J., Wang C., Mao X., Li C., Zhang N., Musi N., DeFronzo R.A., Liu F., Dong L.Q. APPL1 mediates adiponectin-induced LKB1 cytosolic localization through the PP2A-PKCzeta signaling pathway. Mol. Endocrinol. 2011, 25:1773-1785.
135. Hobert J.A., Eng C. PTEN hamartoma tumor syndrome: an overview. Genet. Med. 2009, 11:687-694.
136. Mehenni H., Lin-Marq N., Buchet-Poyau K., Reymond A., Collart M.A., Picard D., Antonarakis S.E. LKB1 interacts with and phosphorylates PTEN: a functional link between two proteins involved in cancer predisposing syndromes. Hum. Mol. Genet. 2005, 14:2209-2219.
137. Song P., Wu Y., Xu J., Xie Z., Dong Y., Zhang M., Zou M.H. Reactive nitrogen species induced by hyperglycemia suppresses Akt signaling and triggers apoptosis by upregulating phosphatase PTEN (phosphatase and tensin homologue deleted on chromosome 10) in an LKB1-dependent manner. Circulation 2007, 116:1585-1595.
138. Liu L., Du X., Nie J. A novel de novo mutation in LKB1 gene in a Chinese Peutz Jeghers syndrome patient significantly diminished p53 activity. Clin. Res. Hepatol. Gastroenterol. 2011, 35:221-226.
139. Shorning B.Y., Griffiths D., Clarke A.R. Lkb1 and Pten synergise to suppress mTOR-mediated tumorigenesis and epithelial-mesenchymal transition in the mouse bladder. PLoS One 2011, 6:e16209.
140. Garcia-Martinez J.M., Wullschleger S., Preston G., Guichard S., Fleming S., Alessi D.R., Duce S.L. Effect of PI3K- and mTOR-specific inhibitors on spontaneous B-cell follicular lymphomas in PTEN/LKB1-deficient mice. Br. J. Cancer 2011, 104:1116-1125.
141. United Kingdom Prospective Diabetes Study (UKPDS) 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 1995, 310:83-88.
142. Diamanti-Kandarakis E., Economou F., Palimeri S., Christakou C. Metformin in polycystic ovary syndrome. Ann. N. Y. Acad. Sci. 2010, 1205:192-198.
143. Bianchi C., Penno G., Romero F., Del Prato S., Miccoli R. Treating the metabolic syndrome. Expert. Rev. Cardiovasc. Ther. 2007, 5:491-506.
144. Viollet B., Guigas B., Sanz Garcia N., Leclerc J., Foretz M., Andreelli F. Cellular and molecular mechanisms of metformin: an overview. Clin. Sci. (Lond.) 2012, 122:253-270.
145. Zhou G., Myers R., Li Y., Chen Y., Shen X., Fenyk-Melody J., Wu M., Ventre J., Doebber T., Fujii N., Musi N., Hirshman M.F., Goodyear L.J., Moller D.E. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 2001, 108:1167-1174.
146. Papanas N., Maltezos E., Mikhailidis D.P. Metformin and cancer: licence to heal?. Expert Opin. Investig. Drugs 2010, 19:913-917.
147. Li J., Zhang B.N., Fan J.H., Pang Y., Zhang P., Wang S.L., Zheng S., Zhang B., Yang H.J., Xie X.M., Tang Z.H., Li H., Li J.Y., He J.J., Qiao Y.L. A nation-wide multicenter 10-year (1999-2008) retrospective clinical epidemiological study of female breast cancer in China. BMC Cancer 2011, 11:364.
148. Goodwin P.J., Pritchard K.I., Ennis M., Clemons M., Graham M., Fantus I.G. Insulin-lowering effects of metformin in women with early breast cancer. Clin. Breast Cancer 2008, 8:501-505.
149. Salani B., Maffioli S., Hamoudane M., Parodi A., Ravera S., Passalacqua M., Alama A., Nhiri M., Cordera R., Maggi D. Caveolin-1 is essential for metformin inhibitory effect on IGF1 action in non-small-cell lung cancer cells. FASEB J. 2012, 26:788-798.
150. Liu B., Fan Z., Edgerton S.M., Yang X., Lind S.E., Thor A.D. Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions. Cell Cycle 2011, 10:2959-2966.
151. Rozengurt E., Sinnett-Smith J., Kisfalvi K. Crosstalk between insulin/insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer. Clin. Cancer Res. 2010, 16:2505-2511.
152. Kisfalvi K., Eibl G., Sinnett-Smith J., Rozengurt E. Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. Cancer Res. 2009, 69:6539-6545.
153. Oliveras-Ferraros C., Vazquez-Martin A., Menendez J.A. Genome-wide inhibitory impact of the AMPK activator metformin on [kinesins, tubulins, histones, auroras and polo-like kinases] M-phase cell cycle genes in human breast cancer cells. Cell Cycle 2009, 8:1633-1636.
154. Alimova I.N., Liu B., Fan Z., Edgerton S.M., Dillon T., Lind S.E., Thor A.D. Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle 2009, 8:909-915.
155. Zhuang Y., Miskimins W.K. Cell cycle arrest in metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1. J. Mol. Signal. 2008, 3:18.
156. Wu N., Gu C., Gu H., Hu H., Han Y., Li Q. Metformin induces apoptosis of lung cancer cells through activating JNK/p38 MAPK pathway and GADD153. Neoplasma 2011, 58:482-490.
157. Malki A., Youssef A. Antidiabetic drug metformin induces apoptosis in human MCF breast cancer via targeting ERK signaling. Oncol. Res. 2011, 19:275-285.
158. Ben Sahra I., Laurent K., Giuliano S., Larbret F., Ponzio G., Gounon P., Le Marchand-Brustel Y., Giorgetti-Peraldi S., Cormont M., Bertolotto C., Deckert M., Auberger P., Tanti J.F., Bost F. Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. Cancer Res. 2010, 70:2465-2475.
159. Yasmeen A., Beauchamp M.C., Piura E., Segal E., Pollak M., Gotlieb W.H. Induction of apoptosis by metformin in epithelial ovarian cancer: involvement of the Bcl-2 family proteins. Gynecol. Oncol. 2011, 121:492-498.
160. Deng X.S., Wang S., Deng A., Liu B., Edgerton S.M., Lind S.E., Wahdan-Alaswad R., Thor A.D. Metformin targets Stat3 to inhibit cell growth and induce apoptosis in triple-negative breast cancers. Cell Cycle 2012, 11:367-376.
161. Rattan R., Graham R.P., Maguire J.L., Giri S., Shridhar V. Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo. Neoplasia 2011, 13:483-491.
162. Phoenix K.N., Vumbaca F., Claffey K.P. Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERalpha negative MDA-MB-435 breast cancer model. Breast Cancer Res. Treat. 2009, 113:101-111.
163. Phoenix K.N., Vumbaca F., Fox M.M., Evans R., Claffey K.P. Dietary energy availability affects primary and metastatic breast cancer and metformin efficacy. Breast Cancer Res. Treat. 2010, 123:333-344.
164. Chen G., Xu S., Renko K., Derwahl M. Metformin inhibits growth of thyroid carcinoma cells, suppresses self-renewal of derived cancer stem cells, and potentiates the effect of chemotherapeutic agents. J. Clin. Endocrinol. Metab. 2012, 97:E510-520.
165. Hirsch H.A., Iliopoulos D., Tsichlis P.N., Struhl K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res. 2009, 69:7507-7511.
166. Hanna R.K., Zhou C., Malloy K.M., Gehrig P.A., Bae-Jump V.L. Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathway. Gynecol. Oncol. 2012, 125:458-469.
167. Kawanami T., Takiguchi S., Ikeda N., Funakoshi A. A humanized anti-IGF-1R monoclonal antibody (R1507) and/or metformin. Oncol. Rep. 2012, 27:867-872.
168. Rocha G.Z., Dias M.M., Ropelle E.R., Osorio-Costa F., Rossato F.A., Vercesi A.E., Saad M.J., Carvalheira J.B. Metformin amplifies chemotherapy-induced AMPK activation and antitumoral growth. Clin. Cancer Res. 2011, 17:3993-4005.
169. Iliopoulos D., Hirsch H.A., Struhl K. Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. Cancer Res. 2011, 71:3196-3201.
170. Hosono K., Endo H., Takahashi H., Sugiyama M., Sakai E., Uchiyama T., Suzuki K., Iida H., Sakamoto Y., Yoneda K., Koide T., Tokoro C., Abe Y., Inamori M., Nakagama H., Nakajima A. Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial. Cancer Prev. Res. (Phila) 2010, 3:1077-1083.
171. Zakikhani M., Dowling R.J., Sonenberg N., Pollak M.N. The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase. Cancer Prev. Res. (Phila) 2008, 1:369-375.
172. Tosca L., Rame C., Chabrolle C., Tesseraud S., Dupont J. Metformin decreases IGF1-induced cell proliferation and protein synthesis through AMP-activated protein kinase in cultured bovine granulosa cells. Reproduction 2010, 139:409-418.
173. Brown K.A., Hunger N.I., Docanto M., Simpson E.R. Metformin inhibits aromatase expression in human breast adipose stromal cells via stimulation of AMP-activated protein kinase. Breast Cancer Res. Treat. 2010, 123:591-596.
174. Janjetovic K., Harhaji-Trajkovic L., Misirkic-Marjanovic M., Vucicevic L., Stevanovic D., Zogovic N., Sumarac-Dumanovic M., Micic D., Trajkovic V. In vitro and in vivo anti-melanoma action of metformin. Eur. J. Pharmacol. 2011, 668:373-382.
175. Rattan R., Giri S., Hartmann L.C., Shridhar V. Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner. J. Cell. Mol. Med. 2011, 15:166-178.
176. Janjetovic K., Vucicevic L., Misirkic M., Vilimanovich U., Tovilovic G., Zogovic N., Nikolic Z., Jovanovic S., Bumbasirevic V., Trajkovic V., Harhaji-Trajkovic L. Metformin reduces cisplatin-mediated apoptotic death of cancer cells through AMPK-independent activation of Akt. Eur. J. Pharmacol. 2011, 651:41-50.
177. El-Mir M.Y., Nogueira V., Fontaine E., Averet N., Rigoulet M., Leverve X. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J. Biol. Chem. 2000, 275:223-228.
178. Owen M.R., Doran E., Halestrap A.P. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem. J. 2000, 348(Pt 3):607-614.
179. Xie Z., Dong Y., Scholz R., Neumann D., Zou M.H. Phosphorylation of LKB1 at serine 428 by protein kinase C-zeta is required for metformin-enhanced activation of the AMP-activated protein kinase in endothelial cells. Circulation 2008, 117:952-962.
180. Shaw R.J., Lamia K.A., Vasquez D., Koo S.H., Bardeesy N., Depinho R.A., Montminy M., Cantley L.C. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 2005, 310:1642-1646.
181. Dowling R.J., Zakikhani M., Fantus I.G., Pollak M., Sonenberg N. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res. 2007, 67:10804-10812.
182. Ouyang J., Parakhia R.A., Ochs R.S. Metformin activates AMP kinase through inhibition of AMP deaminase. J. Biol. Chem. 2011, 286:1-11.
183. Foretz M., Hebrard S., Leclerc J., Zarrinpashneh E., Soty M., Mithieux G., Sakamoto K., Andreelli F., Viollet B. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J. Clin. Invest. 2010, 120:2355-2369.
184. Legro R.S., Barnhart H.X., Schlaff W.D., Carr B.R., Diamond M.P., Carson S.A., Steinkampf M.P., Coutifaris C., McGovern P.G., Cataldo N.A., Gosman G.G., Nestler J.E., Giudice L.C., Ewens K.G., Spielman R.S., Leppert P.C., Myers E.R. Ovulatory response to treatment of polycystic ovary syndrome is associated with a polymorphism in the STK11 gene. J. Clin. Endocrinol. Metab. 2008, 93:792-800.
185. Hadad S., Iwamoto T., Jordan L., Purdie C., Bray S., Baker L., Jellema G., Deharo S., Hardie D.G., Pusztai L., Moulder-Thompson S., Dewar J.A., Thompson A.M. Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial. Breast Cancer Res. Treat. 2011, 128:783-794.
186. LeBrasseur N.K., Kelly M., Tsao T.S., Farmer S.R., Saha A.K., Ruderman N.B., Tomas E. Thiazolidinediones can rapidly activate AMP-activated protein kinase in mammalian tissues. Am. J. Physiol. Endocrinol. Metab. 2006, 291:E175-E181.
187. Sun W., Lee T.S., Zhu M., Gu C., Wang Y., Zhu Y., Shyy J.Y. Statins activate AMP-activated protein kinase in vitro and in vivo. Circulation 2006, 114:2655-2662.
188. Kosaka T., Okuyama R., Sun W., Ogata T., Harada J., Araki K., Izumi M., Yoshida T., Okuno A., Fujiwara T., Ohsumi J., Ichikawa K. Identification of molecular target of AMP-activated protein kinase activator by affinity purification and mass spectrometry. Anal. Chem. 2005, 77:2050-2055.
189. Zang M., Xu S., Maitland-Toolan K.A., Zuccollo A., Hou X., Jiang B., Wierzbicki M., Verbeuren T.J., Cohen R.A. Polyphenols stimulate AMP-activated protein kinase, lower lipids, and inhibit accelerated atherosclerosis in diabetic LDL receptor-deficient mice. Diabetes 2006, 55:2180-2191.
190. Brusq J.M., Ancellin N., Grondin P., Guillard R., Martin S., Saintillan Y., Issandou M. Inhibition of lipid synthesis through activation of AMP kinase: an additional mechanism for the hypolipidemic effects of berberine. J. Lipid Res. 2006, 47:1281-1288.
191. Sullivan J.E., Brocklehurst K.J., Marley A.E., Carey F., Carling D., Beri R.K. Inhibition of lipolysis and lipogenesis in isolated rat adipocytes with AICAR, a cell-permeable activator of AMP-activated protein kinase. FEBS Lett. 1994, 353:33-36.
192. Corton J.M., Gillespie J.G., Hawley S.A., Hardie D.G. 5-aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells?. Eur. J. Biochem. 1995, 229:558-565.
193. Cool B., Zinker B., Chiou W., Kifle L., Cao N., Perham M., Dickinson R., Adler A., Gagne G., Iyengar R., Zhao G., Marsh K., Kym P., Jung P., Camp H.S., Frevert E. Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. Cell Metab. 2006, 3:403-416.
194. Pang T., Zhang Z.S., Gu M., Qiu B.Y., Yu L.F., Cao P.R., Shao W., Su M.B., Li J.Y., Nan F.J., Li J. Small molecule antagonizes autoinhibition and activates AMP-activated protein kinase in cells. J. Biol. Chem. 2008, 283:16051-16060.
195. Scott J.W., van Denderen B.J., Jorgensen S.B., Honeyman J.E., Steinberg G.R., Oakhill J.S., Iseli T.J., Koay A., Gooley P.R., Stapleton D., Kemp B.E. Thienopyridone drugs are selective activators of AMP-activated protein kinase beta1-containing complexes. Chem. Biol. 2008, 15:1220-1230.
196. Xiang X., Saha A.K., Wen R., Ruderman N.B., Luo Z. AMP-activated protein kinase activators can inhibit the growth of prostate cancer cells by multiple mechanisms. Biochem. Biophys. Res. Commun. 2004, 321:161-167.
197. Han S., Roman J. Rosiglitazone suppresses human lung carcinoma cell growth through PPARgamma-dependent and PPARgamma-independent signal pathways. Mol. Cancer Ther. 2006, 5:430-437.
198. Yang P.M., Liu Y.L., Lin Y.C., Shun C.T., Wu M.S., Chen C.C. Inhibition of autophagy enhances anticancer effects of atorvastatin in digestive malignancies. Cancer Res. 2010, 70:7699-7709.
199. Woodard J., Joshi S., Viollet B., Hay N., Platanias L.C. AMPK as a therapeutic target in renal cell carcinoma. Cancer Biol. Ther. 2010, 10:1168-1177.
200. Kim H.S., Kim M.J., Kim E.J., Yang Y., Lee M.S., Lim J.S. Berberine-induced AMPK activation inhibits the metastatic potential of melanoma cells via reduction of ERK activity and COX-2 protein expression. Biochem. Pharmacol. 2012, 83:385-394.
201. Hwang J.T., Kwak D.W., Lin S.K., Kim H.M., Kim Y.M., Park O.J. Resveratrol induces apoptosis in chemoresistant cancer cells via modulation of AMPK signaling pathway. Ann. N. Y. Acad. Sci. 2007, 1095:441-448.
202. Baumann P., Mandl-Weber S., Emmerich B., Straka C., Schmidmaier R. Activation of adenosine monophosphate activated protein kinase inhibits growth of multiple myeloma cells. Exp. Cell Res. 2007, 313:3592-3603.
203. Liu B., Fan Z., Edgerton S.M., Deng X.S., Alimova I.N., Lind S.E., Thor A.D. Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle 2009, 8:2031-2040.
204. Zakikhani M., Dowling R., Fantus I.G., Sonenberg N., Pollak M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res. 2006, 66:10269-10273.
205. Zhuang Y., Miskimins W.K. Metformin induces both caspase-dependent and poly(ADP-ribose) polymerase-dependent cell death in breast cancer cells. Mol. Cancer Res. 2011, 9:603-615.
206. Vazquez-Martin A., Oliveras-Ferraros C., Cufi S., Del Barco S., Martin-Castillo B., Lopez-Bonet E., Menendez J.A. The anti-diabetic drug metformin suppresses the metastasis-associated protein CD24 in MDA-MB-468 triple-negative breast cancer cells. Oncol. Rep. 2011, 25:135-140.
207. Wang L.W., Li Z.S., Zou D.W., Jin Z.D., Gao J., Xu G.M. Metformin induces apoptosis of pancreatic cancer cells. World J. Gastroenterol. 2008, 14:7192-7198.
208. Bao B., Wang Z., Ali S., Ahmad A., Azmi A.S., Sarkar S.H., Banerjee S., Kong D., Li Y., Thakur S., Sarkar F.H. Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells. Cancer Prev. Res. (Phila) 2012, 5:355-364.
209. Buzzai M., Jones R.G., Amaravadi R.K., Lum J.J., DeBerardinis R.J., Zhao F., Viollet B., Thompson C.B. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res. 2007, 67:6745-6752.
210. Kato K., Gong J., Iwama H., Kitanaka A., Tani J., Miyoshi H., Nomura K., Mimura S., Kobayashi M., Aritomo Y., Kobara H., Mori H., Himoto T., Okano K., Suzuki Y., Murao K., Masaki T. The antidiabetic drug metformin inhibits gastric cancer cell proliferation in vitro and in vivo. Mol. Cancer Ther. 2012, 11:549-560.
211. Tan B.K., Adya R., Chen J., Lehnert H., Sant Cassia L.J., Randeva H.S. Metformin treatment exerts antiinvasive and antimetastatic effects in human endometrial carcinoma cells. J. Clin. Endocrinol. Metab. 2011, 96:808-816.
212. Vakana E., Altman J.K., Glaser H., Donato N.J., Platanias L.C. Antileukemic effects of AMPK activators on BCR-ABL-expressing cells. Blood 2011, 118:6399-6402.
213. Ben Sahra I., Laurent K., Loubat A., Giorgetti-Peraldi S., Colosetti P., Auberger P., Tanti J.F., Le Marchand-Brustel Y., Bost F. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 2008, 27:3576-3586.
214. Schneider M.B., Matsuzaki H., Haorah J., Ulrich A., Standop J., Ding X.Z., Adrian T.E., Pour P.M. Prevention of pancreatic cancer induction in hamsters by metformin. Gastroenterology 2001, 120:1263-1270.
215. Algire C., Amrein L., Zakikhani M., Panasci L., Pollak M. Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase. Endocr. Relat. Cancer 2010, 17:351-360.
216. Hosono K., Endo H., Takahashi H., Sugiyama M., Uchiyama T., Suzuki K., Nozaki Y., Yoneda K., Fujita K., Yoneda M., Inamori M., Tomatsu A., Chihara T., Shimpo K., Nakagama H., Nakajima A. Metformin suppresses azoxymethane-induced colorectal aberrant crypt foci by activating AMP-activated protein kinase. Mol. Carcinog. 2010, 49:662-671.
217. Tomimoto A., Endo H., Sugiyama M., Fujisawa T., Hosono K., Takahashi H., Nakajima N., Nagashima Y., Wada K., Nakagama H., Nakajima A. Metformin suppresses intestinal polyp growth in ApcMin/+ mice. Cancer Sci. 2008, 99:2136-2141.
218. Bojkova B., Orendas P., Garajova M., Kassayova M., Kutna V., Ahlersova E., Ahlers I. Metformin in chemically-induced mammary carcinogenesis in rats. Neoplasma 2009, 56:269-274.
219. Anisimov V.N., Berstein L.M., Egormin P.A., Piskunova T.S., Popovich I.G., Zabezhinski M.A., Kovalenko I.G., Poroshina T.E., Semenchenko A.V., Provinciali M., Re F., Franceschi C. Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Exp. Gerontol. 2005, 40:685-693.
220. Memmott R.M., Mercado J.R., Maier C.R., Kawabata S., Fox S.D., Dennis P.A. Metformin prevents tobacco carcinogen-induced lung tumorigenesis. Cancer Prev. Res. (Phila) 2010, 3:1066-1076.
221. Yu X., Carpenter P., Anasetti C. Advances in transplantation tolerance. Lancet 2001, 357:1959-1963.
222. Chung J., Kuo C.J., Crabtree G.R., Blenis J. Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases. Cell 1992, 69:1227-1236.
223. Asano T., Yao Y., Zhu J., Li D., Abbruzzese J.L., Reddy S.A. The rapamycin analog CCI-779 is a potent inhibitor of pancreatic cancer cell proliferation. Biochem. Biophys. Res. Commun. 2005, 331:295-302.
224. Yu K., Toral-Barza L., Discafani C., Zhang W.G., Skotnicki J., Frost P., Gibbons J.J. mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr. Relat. Cancer 2001, 8:249-258.
225. Thomas G.V., Tran C., Mellinghoff I.K., Welsbie D.S., Chan E., Fueger B., Czernin J., Sawyers C.L. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat. Med. 2006, 12:122-127.
226. Wu L., Birle D.C., Tannock I.F. Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. Cancer Res. 2005, 65:2825-2831.
227. Boffa D.J., Luan F., Thomas D., Yang H., Sharma V.K., Lagman M., Suthanthiran M. Rapamycin inhibits the growth and metastatic progression of non-small cell lung cancer. Clin. Cancer Res. 2004, 10:293-300.
228. Ito D., Fujimoto K., Mori T., Kami K., Koizumi M., Toyoda E., Kawaguchi Y., Doi R. In vivo antitumor effect of the mTOR inhibitor CCI-779 and gemcitabine in xenograft models of human pancreatic cancer. Int. J. Cancer 2006, 118:2337-2343.
229. Okada T., Sawada T., Kubota K. Rapamycin enhances the anti-tumor effect of gemcitabine in pancreatic cancer cells. Hepatogastroenterology 2007, 54:2129-2133.
230. Manegold P.C., Paringer C., Kulka U., Krimmel K., Eichhorn M.E., Wilkowski R., Jauch K.W., Guba M., Bruns C.J. Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (Everolimus) increases radiosensitivity in solid cancer. Clin. Cancer Res. 2008, 14:892-900.
231. Paglin S., Lee N.Y., Nakar C., Fitzgerald M., Plotkin J., Deuel B., Hackett N., McMahill M., Sphicas E., Lampen N., Yahalom J. Rapamycin-sensitive pathway regulates mitochondrial membrane potential, autophagy, and survival in irradiated MCF-7 cells. Cancer Res. 2005, 65:11061-11070.
232. van Veelen W., Korsse S.E., van de Laar L., Peppelenbosch M.P. The long and winding road to rational treatment of cancer associated with LKB1/AMPK/TSC/mTORC1 signaling. Oncogene 2011, 30:2289-2303.
233. Hudes G., Carducci M., Tomczak P., Dutcher J., Figlin R., Kapoor A., Staroslawska E., Sosman J., McDermott D., Bodrogi I., Kovacevic Z., Lesovoy V., Schmidt-Wolf I.G., Barbarash O., Gokmen E., O'Toole T., Lustgarten S., Moore L., Motzer R.J. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 2007, 356:2271-2281.
234. Motzer R.J., Escudier B., Oudard S., Hutson T.E., Porta C., Bracarda S., Grunwald V., Thompson J.A., Figlin R.A., Hollaender N., Urbanowitz G., Berg W.J., Kay A., Lebwohl D., Ravaud A. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008, 372:449-456.
235. Motzer R.J., Escudier B., Oudard S., Hutson T.E., Porta C., Bracarda S., Grunwald V., Thompson J.A., Figlin R.A., Hollaender N., Kay A., Ravaud A. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010, 116:4256-4265.
236. Bissler J.J., McCormack F.X., Young L.R., Elwing J.M., Chuck G., Leonard J.M., Schmithorst V.J., Laor T., Brody A.S., Bean J., Salisbury S., Franz D.N. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N. Engl. J. Med. 2008, 358:140-151.
237. Davies D.M., Johnson S.R., Tattersfield A.E., Kingswood J.C., Cox J.A., McCartney D.L., Doyle T., Elmslie F., Saggar A., de Vries P.J., Sampson J.R. Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis. N. Engl. J. Med. 2008, 358:200-203.
238. Davies D.M., de Vries P.J., Johnson S.R., McCartney D.L., Cox J.A., Serra A.L., Watson P.C., Howe C.J., Doyle T., Pointon K., Cross J.J., Tattersfield A.E., Kingswood J.C., Sampson J.R. Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial. Clin. Cancer Res. 2011, 17:4071-4081.
239. Krueger D.A., Care M.M., Holland K., Agricola K., Tudor C., Mangeshkar P., Wilson K.A., Byars A., Sahmoud T., Franz D.N. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N. Engl. J. Med. 2010, 363:1801-1811.
240. Dabora S.L., Franz D.N., Ashwal S., Sagalowsky A., DiMario F.J., Miles D., Cutler D., Krueger D., Uppot R.N., Rabenou R., Camposano S., Paolini J., Fennessy F., Lee N., Woodrum C., Manola J., Garber J., Thiele E.A. Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and VEGF-D levels decrease. PLoS One 2011, 6:e23379.
241. Yao J.C., Phan A.T., Chang D.Z., Wolff R.A., Hess K., Gupta S., Jacobs C., Mares J.E., Landgraf A.N., Rashid A., Meric-Bernstam F. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J. Clin. Oncol. 2008, 26:4311-4318.
242. Yao J.C., Lombard-Bohas C., Baudin E., Kvols L.K., Rougier P., Ruszniewski P., Hoosen S., St Peter J., Haas T., Lebwohl D., Van Cutsem E., Kulke M.H., Hobday T.J., O'Dorisio T.M., Shah M.H., Cadiot G., Luppi G., Posey J.A., Wiedenmann B. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J. Clin. Oncol. 2010, 28:69-76.
243. Pavel M.E., Hainsworth J.D., Baudin E., Peeters M., Horsch D., Winkler R.E., Klimovsky J., Lebwohl D., Jehl V., Wolin E.M., Oberg K., Van Cutsem E., Yao J.C. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 2011, 378:2005-2012.
244. Bhagwat S.V., Gokhale P.C., Crew A.P., Cooke A., Yao Y., Mantis C., Kahler J., Workman J., Bittner M., Dudkin L., Epstein D.M., Gibson N.W., Wild R., Arnold L.D., Houghton P.J., Pachter J.A. Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin. Mol. Cancer Ther. 2011, 10:1394-1406.
245. Conde E., Angulo B., Tang M., Morente M., Torres-Lanzas J., Lopez-Encuentra A., Lopez-Rios F., Sanchez-Cespedes M. Molecular context of the EGFR mutations: evidence for the activation of mTOR/S6K signaling. Clin. Cancer Res. 2006, 12:710-717.
246. Balsara B.R., Pei J., Mitsuuchi Y., Page R., Klein-Szanto A., Wang H., Unger M., Testa J.R. Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis 2004, 25:2053-2059.
247. Price K.A., Azzoli C.G., Krug L.M., Pietanza M.C., Rizvi N.A., Pao W., Kris M.G., Riely G.J., Heelan R.T., Arcila M.E., Miller V.A. Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer. J. Thorac. Oncol. 2010, 5:1623-1629.
248. Pandolfi P.P. Breast cancer-loss of PTEN predicts resistance to treatment. N. Engl. J. Med. 2004, 351:2337-2338.
249. Tokunaga E., Kimura Y., Mashino K., Oki E., Kataoka A., Ohno S., Morita M., Kakeji Y., Baba H., Maehara Y. Activation of PI3K/Akt signaling and hormone resistance in breast cancer. Breast Cancer 2006, 13:137-144.
250. Baselga J., Campone M., Piccart M., Burris H.A., Rugo H.S., Sahmoud T., Noguchi S., Gnant M., Pritchard K.I., Lebrun F., Beck J.T., Ito Y., Yardley D., Deleu I., Perez A., Bachelot T., Vittori L., Xu Z., Mukhopadhyay P., Lebwohl D., Hortobagyi G.N. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N. Engl. J. Med. 2012, 366:520-529.
251. Nozawa H., Watanabe T., Nagawa H. Phosphorylation of ribosomal p70 S6 kinase and rapamycin sensitivity in human colorectal cancer. Cancer Lett. 2007, 251:105-113.
252. Zhang Y.J., Dai Q., Sun D.F., Xiong H., Tian X.Q., Gao F.H., Xu M.H., Chen G.Q., Han Z.G., Fang J.Y. mTOR signaling pathway is a target for the treatment of colorectal cancer. Ann. Surg. Oncol. 2009, 16:2617-2628.
253. Altomare I., Bendell J.C., Bullock K.E., Uronis H.E., Morse M.A., Hsu S.D., Zafar S.Y., Blobe G.C., Pang H., Honeycutt W., Sutton L., Hurwitz H.I. A phase II trial of bevacizumab plus everolimus for patients with refractory metastatic colorectal cancer. Oncologist 2011, 16:1131-1137.
254. Chresta C.M., Davies B.R., Hickson I., Harding T., Cosulich S., Critchlow S.E., Vincent J.P., Ellston R., Jones D., Sini P., James D., Howard Z., Dudley P., Hughes G., Smith L., Maguire S., Hummersone M., Malagu K., Menear K., Jenkins R., Jacobsen M., Smith G.C., Guichard S., Pass M. AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res. 2010, 70:288-298.
255. Jiang Q., Weiss J.M., Back T., Chan T., Ortaldo J.R., Guichard S., Wiltrout R.H. mTOR kinase inhibitor AZD8055 enhances the immunotherapeutic activity of an agonist CD40 antibody in cancer treatment. Cancer Res. 2011, 71:4074-4084.
256. Janes M.R., Limon J.J., So L., Chen J., Lim R.J., Chavez M.A., Vu C., Lilly M.B., Mallya S., Ong S.T., Konopleva M., Martin M.B., Ren P., Liu Y., Rommel C., Fruman D.A. Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat. Med. 2010, 16:205-213.
257. Yu K., Toral-Barza L., Shi C., Zhang W.G., Lucas J., Shor B., Kim J., Verheijen J., Curran K., Malwitz D.J., Cole D.C., Ellingboe J., Ayral-Kaloustian S., Mansour T.S., Gibbons J.J., Abraham R.T., Nowak P., Zask A. Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. Cancer Res. 2009, 69:6232-6240.
258. Yu K., Shi C., Toral-Barza L., Lucas J., Shor B., Kim J.E., Zhang W.G., Mahoney R., Gaydos C., Tardio L., Kim S.K., Conant R., Curran K., Kaplan J., Verheijen J., Ayral-Kaloustian S., Mansour T.S., Abraham R.T., Zask A., Gibbons J.J. Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2. Cancer Res. 2010, 70:621-631.
259. Garcia-Martinez J.M., Moran J., Clarke R.G., Gray A., Cosulich S.C., Chresta C.M., Alessi D.R. Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR). Biochem. J. 2009, 421:29-42.
260. Chen S.M., Liu J.L., Wang X., Liang C., Ding J., Meng L.H. Inhibition of tumor cell growth, proliferation and migration by X-387, a novel active-site inhibitor of mTOR. Biochem. Pharmacol. 2012, 83:1183-1194.
261. Wei C., Amos C.I., Zhang N., Wang X., Rashid A., Walker C.L., Behringer R.R., Frazier M.L. Suppression of Peutz-Jeghers polyposis by targeting mammalian target of rapamycin signaling. Clin. Cancer Res. 2008, 14:1167-1171.
262. Robinson J., Lai C., Martin A., Nye E., Tomlinson I., Silver A. Oral rapamycin reduces tumour burden and vascularization in Lkb1(+/-) mice. J. Pathol. 2009, 219:35-40.
263. Shackelford D.B., Vasquez D.S., Corbeil J., Wu S., Leblanc M., Wu C.L., Vera D.R., Shaw R.J. mTOR and HIF-1alpha-mediated tumor metabolism in an LKB1 mouse model of Peutz-Jeghers syndrome. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:11137-11142.
264. Wei C., Amos C.I., Zhang N., Zhu J., Wang X., Frazier M.L. Chemopreventive efficacy of rapamycin on Peutz-Jeghers syndrome in a mouse model. Cancer Lett. 2009, 277:149-154.
265. Fujishita T., Aoki K., Lane H.A., Aoki M., Taketo M.M. Inhibition of the mTORC1 pathway suppresses intestinal polyp formation and reduces mortality in ApcDelta716 mice. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:13544-13549.
266. Koehl G.E., Spitzner M., Ousingsawat J., Schreiber R., Geissler E.K., Kunzelmann K. Rapamycin inhibits oncogenic intestinal ion channels and neoplasia in APC(Min/+) mice. Oncogene 2010, 29:1553-1560.
267. Hung K.E., Maricevich M.A., Richard L.G., Chen W.Y., Richardson M.P., Kunin A., Bronson R.T., Mahmood U., Kucherlapati R. Development of a mouse model for sporadic and metastatic colon tumors and its use in assessing drug treatment. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:1565-1570.
268. Johannessen C.M., Johnson B.W., Williams S.M., Chan A.W., Reczek E.E., Lynch R.C., Rioth M.J., McClatchey A., Ryeom S., Cichowski K. TORC1 is essential for NF1-associated malignancies. Curr. Biol. 2008, 18:56-62.
269. Lee L., Sudentas P., Donohue B., Asrican K., Worku A., Walker V., Sun Y., Schmidt K., Albert M.S., El-Hashemite N., Lader A.S., Onda H., Zhang H., Kwiatkowski D.J., Dabora S.L. Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models. Genes Chromosom. Cancer 2005, 42:213-227.
270. Lee N., Woodrum C.L., Nobil A.M., Rauktys A.E., Messina M.P., Dabora S.L. Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models. BMC Pharmacol. 2009, 9:8.
271. Pollizzi K., Malinowska-Kolodziej I., Stumm M., Lane H., Kwiatkowski D. Equivalent benefit of mTORC1 blockade and combined PI3K-mTOR blockade in a mouse model of tuberous sclerosis. Mol. Cancer 2009, 8:38.
272. Podsypanina K., Lee R.T., Politis C., Hennessy I., Crane A., Puc J., Neshat M., Wang H., Yang L., Gibbons J., Frost P., Dreisbach V., Blenis J., Gaciong Z., Fisher P., Sawyers C., Hedrick-Ellenson L., Parsons R. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/-mice. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:10320-10325.
273. Contreras C.M., Akbay E.A., Gallardo T.D., Haynie J.M., Sharma S., Tagao O., Bardeesy N., Takahashi M., Settleman J., Wong K.K., Castrillon D.H. Lkb1 inactivation is sufficient to drive endometrial cancers that are aggressive yet highly responsive to mTOR inhibitor monotherapy. Dis. Model. Mech. 2010, 3:181-193.
274. Mabuchi S., Altomare D.A., Connolly D.C., Klein-Szanto A., Litwin S., Hoelzle M.K., Hensley H.H., Hamilton T.C., Testa J.R. RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer. Cancer Res. 2007, 67:2408-2413.
275. Wu R., Hu T.C., Rehemtulla A., Fearon E.R., Cho K.R. Preclinical testing of PI3K/AKT/mTOR signaling inhibitors in a mouse model of ovarian endometrioid adenocarcinoma. Clin. Cancer Res. 2011, 17:7359-7372.
276. Guigon C.J., Fozzatti L., Lu C., Willingham M.C., Cheng S.Y. Inhibition of mTORC1 signaling reduces tumor growth but does not prevent cancer progression in a mouse model of thyroid cancer. Carcinogenesis 2010, 31:1284-1291.
277. Puzio-Kuter A.M., Castillo-Martin M., Kinkade C.W., Wang X., Shen T.H., Matos T., Shen M.M., Cordon-Cardo C., Abate-Shen C. Inactivation of p53 and Pten promotes invasive bladder cancer. Genes Dev. 2009, 23:675-680.
278. Zhang W., Zhu J., Efferson C.L., Ware C., Tammam J., Angagaw M., Laskey J., Bettano K.A., Kasibhatla S., Reilly J.F., Sur C., Majumder P.K. Inhibition of tumor growth progression by antiandrogens and mTOR inhibitor in a Pten-deficient mouse model of prostate cancer. Cancer Res. 2009, 69:7466-7472.
279. Majumder P.K., Febbo P.G., Bikoff R., Berger R., Xue Q., McMahon L.M., Manola J., Brugarolas J., McDonnell T.J., Golub T.R., Loda M., Lane H.A., Sellers W.R. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat. Med. 2004, 10:594-601.
280. Liu M., Howes A., Lesperance J., Stallcup W.B., Hauser C.A., Kadoya K., Oshima R.G., Abraham R.T. Antitumor activity of rapamycin in a transgenic mouse model of ErbB2-dependent human breast cancer. Cancer Res. 2005, 65:5325-5336.
281. Mosley J.D., Poirier J.T., Seachrist D.D., Landis M.D., Keri R.A. Rapamycin inhibits multiple stages of c-Neu/ErbB2 induced tumor progression in a transgenic mouse model of HER2-positive breast cancer. Mol. Cancer Ther. 2007, 6:2188-2197.
282. Wang X., Zhan Y., Zhao L., Alvarez J., Chaudhary I., Zhou B.B., Abraham R.T., Feuerstein G.Z. Multimodal biomarker investigation on efficacy and mechanism of action for the mammalian target of rapamycin inhibitor, temsirolimus, in a preclinical mammary carcinoma OncoMouse model: a translational medicine study in support for early clinical development. J. Pharmacol. Exp. Ther. 2011, 339:421-429.
283. Wu Q., Kiguchi K., Kawamoto T., Ajiki T., Traag J., Carbajal S., Ruffino L., Thames H., Wistuba I., Thomas M., Vasquez K.M., DiGiovanni J. Therapeutic effect of rapamycin on gallbladder cancer in a transgenic mouse model. Cancer Res. 2007, 67:3794-3800.
284. Xing D., Orsulic S. A genetically defined mouse ovarian carcinoma model for the molecular characterization of pathway-targeted therapy and tumor resistance. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:6936-6941.
285. Wendel H.G., Malina A., Zhao Z., Zender L., Kogan S.C., Cordon-Cardo C., Pelletier J., Lowe S.W. Determinants of sensitivity and resistance to rapamycin-chemotherapy drug combinations in vivo. Cancer Res. 2006, 66:7639-7646.
286. Buck E., Eyzaguirre A., Brown E., Petti F., McCormack S., Haley J.D., Iwata K.K., Gibson N.W., Griffin G. Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors. Mol. Cancer Ther. 2006, 5:2676-2684.
287. Azzariti A., Porcelli L., Gatti G., Nicolin A., Paradiso A. Synergic antiproliferative and antiangiogenic effects of EGFR and mTor inhibitors on pancreatic cancer cells. Biochem. Pharmacol. 2008, 75:1035-1044.
288. Mueller M.T., Hermann P.C., Witthauer J., Rubio-Viqueira B., Leicht S.F., Huber S., Ellwart J.W., Mustafa M., Bartenstein P., D'Haese J.G., Schoenberg M.H., Berger F., Jauch K.W., Hidalgo M., Heeschen C. Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer. Gastroenterology 2009, 137:1102-1113.
289. Chang Q., Chen E., Hedley D.W. Effects of combined inhibition of MEK and mTOR on downstream signaling and tumor growth in pancreatic cancer xenograft models. Cancer Biol. Ther. 2009, 8:1893-1901.
290. Bianco R., Garofalo S., Rosa R., Damiano V., Gelardi T., Daniele G., Marciano R., Ciardiello F., Tortora G. Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs. Br. J. Cancer 2008, 98:923-930.
291. Wang L.H., Chan J.L., Li W. Rapamycin together with herceptin significantly increased anti-tumor efficacy compared to either alone in ErbB2 over expressing breast cancer cells. Int. J. Cancer 2007, 121:157-164.
292. Mi R., Ma J., Zhang D., Li L., Zhang H. Efficacy of combined inhibition of mTOR and ERK/MAPK pathways in treating a tuberous sclerosis complex cell model. J. Genet. Genomics 2009, 36:355-361.
293. Buonamici S., Williams J., Morrissey M., Wang A., Guo R., Vattay A., Hsiao K., Yuan J., Green J., Ospina B., Yu Q., Ostrom L., Fordjour P., Anderson D.L., Monahan J.E., Kelleher J.F., Peukert S., Pan S., Wu X., Maira S.M., Garcia-Echeverria C., Briggs K.J., Watkins D.N., Yao Y.M., Lengauer C., Warmuth M., Sellers W.R., Dorsch M. Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. Sci. Transl. Med. 2010, 2:51ra70.
294. Shi H., Kong X., Ribas A., Lo R.S. Combinatorial treatments that overcome PDGFRbeta-driven resistance of melanoma cells to V600EB-RAF inhibition. Cancer Res. 2011, 71:5067-5074.
295. Shimizu T., Tolcher A.W., Papadopoulos K.P., Beeram M., Rasco D., Smith L.S., Gunn S., Smetzer L., Mays T.A., Kaiser B., Wick M.J., Alvarez C., Cavazos A., Mangold G.L., Patnaik A. The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. Clin. Cancer Res. 2012, 18:2316-2325.
296. Zitzmann K., Ruden J., Brand S., Goke B., Lichtl J., Spottl G., Auernhammer C.J. Compensatory activation of Akt in response to mTOR and Raf inhibitors - a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease. Cancer Lett. 2010, 295:100-109.
297. Banerjee S., Gianino S.M., Gao F., Christians U., Gutmann D.H. Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes. Mol. Cancer Ther. 2011, 10:279-291.
298. Marone R., Erhart D., Mertz A.C., Bohnacker T., Schnell C., Cmiljanovic V., Stauffer F., Garcia-Echeverria C., Giese B., Maira S.M., Wymann M.P. Targeting melanoma with dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors. Mol. Cancer Res. 2009, 7:601-613.
299. Elfiky A.A., Aziz S.A., Conrad P.J., Siddiqui S., Hackl W., Maira M., Robert C.L., Kluger H.M. Characterization and targeting of phosphatidylinositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in renal cell cancer. J. Transl. Med 2011, 9:133.
300. Cho D.C., Cohen M.B., Panka D.J., Collins M., Ghebremichael M., Atkins M.B., Signoretti S., Mier J.W. The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma. Clin. Cancer Res. 2010, 16:3628-3638.
301. Maira S.M., Stauffer F., Brueggen J., Furet P., Schnell C., Fritsch C., Brachmann S., Chene P., De Pover A., Schoemaker K., Fabbro D., Gabriel D., Simonen M., Murphy L., Finan P., Sellers W., Garcia-Echeverria C. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol. Cancer Ther. 2008, 7:1851-1863.
302. Cao P., Maira S.M., Garcia-Echeverria C., Hedley D.W. Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts. Br. J. Cancer 2009, 100:1267-1276.
303. McMillin D.W., Ooi M., Delmore J., Negri J., Hayden P., Mitsiades N., Jakubikova J., Maira S.M., Garcia-Echeverria C., Schlossman R., Munshi N.C., Richardson P.G., Anderson K.C., Mitsiades C.S. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235. Cancer Res. 2009, 69:5835-5842.
304. Bhatt A.P., Bhende P.M., Sin S.H., Roy D., Dittmer D.P., Damania B. Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas. Blood 2010, 115:4455-4463.
305. Chiarini F., Grimaldi C., Ricci F., Tazzari P.L., Evangelisti C., Ognibene A., Battistelli M., Falcieri E., Melchionda F., Pession A., Pagliaro P., McCubrey J.A., Martelli A.M. Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia. Cancer Res. 2010, 70:8097-8107.
306. Roper J., Richardson M.P., Wang W.V., Richard L.G., Chen W., Coffee E.M., Sinnamon M.J., Lee L., Chen P.C., Bronson R.T., Martin E.S., Hung K.E. The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer. PLoS One 2011, 6:e25132.
307. Herrera V.A., Zeindl-Eberhart E., Jung A., Huber R.M., Bergner A. The dual PI3K/mTOR inhibitor BEZ235 is effective in lung cancer cell lines. Anticancer. Res. 2011, 31:849-854.
308. Santiskulvong C., Konecny G.E., Fekete M., Chen K.Y., Karam A., Mulholland D., Eng C., Wu H., Song M., Dorigo O. Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma. Clin. Cancer Res. 2011, 17:2373-2384.
309. Serra V., Markman B., Scaltriti M., Eichhorn P.J., Valero V., Guzman M., Botero M.L., Llonch E., Atzori F., Di Cosimo S., Maira M., Garcia-Echeverria C., Parra J.L., Arribas J., Baselga J. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res. 2008, 68:8022-8030.
310. Brachmann S.M., Hofmann I., Schnell C., Fritsch C., Wee S., Lane H., Wang S., Garcia-Echeverria C., Maira S.M. Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:22299-22304.
311. Brunner-Kubath C., Shabbir W., Saferding V., Wagner R., Singer C.F., Valent P., Berger W., Marian B., Zielinski C.C., Grusch M., Grunt T.W. The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells. Breast Cancer Res. Treat. 2011, 129:387-400.
312. Eichhorn P.J., Gili M., Scaltriti M., Serra V., Guzman M., Nijkamp W., Beijersbergen R.L., Valero V., Seoane J., Bernards R., Baselga J. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res. 2008, 68:9221-9230.
313. Konstantinidou G., Bey E.A., Rabellino A., Schuster K., Maira M.S., Gazdar A.F., Amici A., Boothman D.A., Scaglioni P.P. Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations. Cancer Res. 2009, 69:7644-7652.
314. Faber A.C., Li D., Song Y., Liang M.C., Yeap B.Y., Bronson R.T., Lifshits E., Chen Z., Maira S.M., Garcia-Echeverria C., Wong K.K., Engelman J.A. Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:19503-19508.
315. Schult C., Dahlhaus M., Glass A., Fischer K., Lange S., Freund M., Junghanss C. The dual kinase inhibitor NVP-BEZ235 in combination with cytotoxic drugs exerts anti-proliferative activity towards acute lymphoblastic leukemia cells. Anticancer. Res. 2012, 32:463-474.
316. Fokas E., Im J.H., Hill S., Yameen S., Stratford M., Beech J., Hackl W., Maira S.M., Bernhard E.J., McKenna W.G., Muschel R.J. Dual inhibition of the PI3K/mTOR pathway increases tumor radiosensitivity by normalizing tumor vasculature. Cancer Res. 2012, 72:239-248.
317. Awasthi N., Yen P.L., Schwarz M.A., Schwarz R.E. The efficacy of a novel, dual PI3K/mTOR inhibitor NVP-BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer. J. Cell. Biochem. 2012, 113:784-791.
318. Dubrovska A., Elliott J., Salamone R.J., Kim S., Aimone L.J., Walker J.R., Watson J., Sauveur-Michel M., Garcia-Echeverria C., Cho C.Y., Reddy V.A., Schultz P.G. Combination therapy targeting both tumor-initiating and differentiated cell populations in prostate carcinoma. Clin. Cancer Res. 2010, 16:5692-5702.
319. Engelman J.A., Chen L., Tan X., Crosby K., Guimaraes A.R., Upadhyay R., Maira M., McNamara K., Perera S.A., Song Y., Chirieac L.R., Kaur R., Lightbown A., Simendinger J., Li T., Padera R.F., Garcia-Echeverria C., Weissleder R., Mahmood U., Cantley L.C., Wong K.K. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat. Med. 2008, 14:1351-1356.
320. Sunayama J., Matsuda K., Sato A., Tachibana K., Suzuki K., Narita Y., Shibui S., Sakurada K., Kayama T., Tomiyama A., Kitanaka C. Crosstalk between the PI3K/mTOR and MEK/ERK pathways involved in the maintenance of self-renewal and tumorigenicity of glioblastoma stem-like cells. Stem Cells 2010, 28:1930-1939.
321. Jin N., Jiang T., Rosen D.M., Nelkin B.D., Ball D.W. Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer. Clin. Cancer Res. 2011, 17:6482-6489.
322. Roulin D., Waselle L., Dormond-Meuwly A., Dufour M., Demartines N., Dormond O. Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib. Mol. Cancer 2011, 10:90.
323. Kharas M.G., Janes M.R., Scarfone V.M., Lilly M.B., Knight Z.A., Shokat K.M., Fruman D.A. Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+leukemia cells. J. Clin. Invest. 2008, 118:3038-3050.
324. Zou C.Y., Smith K.D., Zhu Q.S., Liu J., McCutcheon I.E., Slopis J.M., Meric-Bernstam F., Peng Z., Bornmann W.G., Mills G.B., Lazar A.J., Pollock R.E., Lev D. Dual targeting of AKT and mammalian target of rapamycin: a potential therapeutic approach for malignant peripheral nerve sheath tumor. Mol. Cancer Ther. 2009, 8:1157-1168.
325. Werzowa J., Koehrer S., Strommer S., Cejka D., Fuereder T., Zebedin E., Wacheck V. Vertical inhibition of the mTORC1/mTORC2/PI3K pathway shows synergistic effects against melanoma in vitro and in vivo. J. Investig. Dermatol. 2011, 131:495-503.
326. Yuan J., Mehta P.P., Yin M.J., Sun S., Zou A., Chen J., Rafidi K., Feng Z., Nickel J., Engebretsen J., Hallin J., Blasina A., Zhang E., Nguyen L., Sun M., Vogt P.K., McHarg A., Cheng H., Christensen J.G., Kan J.L., Bagrodia S. PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity. Mol. Cancer Ther. 2011, 10:2189-2199.
327. Kinross K.M., Brown D.V., Kleinschmidt M., Jackson S., Christensen J., Cullinane C., Hicks R.J., Johnstone R.W., McArthur G.A. In vivo activity of combined PI3K/mTOR and MEK inhibition in a Kras(G12D);Pten deletion mouse model of ovarian cancer. Mol. Cancer Ther. 2011, 10:1440-1449.
328. Sutherlin D.P., Bao L., Berry M., Castanedo G., Chuckowree I., Dotson J., Folks A., Friedman L., Goldsmith R., Gunzner J., Heffron T., Lesnick J., Lewis C., Mathieu S., Murray J., Nonomiya J., Pang J., Pegg N., Prior W.W., Rouge L., Salphati L., Sampath D., Tian Q., Tsui V., Wan N.C., Wang S., Wei B., Wiesmann C., Wu P., Zhu B.Y., Olivero A. Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer. J. Med. Chem. 2011, 54:7579-7587.
329. Wallin J.J., Edgar K.A., Guan J., Berry M., Prior W.W., Lee L., Lesnick J.D., Lewis C., Nonomiya J., Pang J., Salphati L., Olivero A.G., Sutherlin D.P., O'Brien C., Spoerke J.M., Patel S., Lensun L., Kassees R., Ross L., Lackner M.R., Sampath D., Belvin M., Friedman L.S. GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway. Mol. Cancer Ther. 2011, 10:2426-2436.
330. Baumann P., Schneider L., Mandl-Weber S., Oduncu F., Schmidmaier R. Simultaneous targeting of PI3K and mTOR with NVP-BGT226 is highly effective in multiple myeloma. Anticancer Drugs 2012, 23:131-138.
331. Chang K.Y., Tsai S.Y., Wu C.M., Yen C.J., Chuang B.F., Chang J.Y. Novel phosphoinositide 3-kinase/mTOR dual inhibitor, NVP-BGT226, displays potent growth-inhibitory activity against human head and neck cancer cells in vitro and in vivo. Clin. Cancer Res. 2011, 17:7116-7126.
332. Glienke W., Maute L., Wicht J., Bergmann L. The dual PI3K/mTOR inhibitor NVP-BGT226 induces cell cycle arrest and regulates Survivin gene expression in human pancreatic cancer cell lines. Tumour Biol. 2011, 33:757-765.
333. Leung E., Kim J.E., Rewcastle G.W., Finlay G.J., Baguley B.C. Comparison of the effects of the PI3K/mTOR inhibitors NVP-BEZ235 and GSK2126458 on tamoxifen-resistant breast cancer cells. Cancer Biol. Ther. 2011, 11:938-946.
334. Dehnhardt C.M., Venkatesan A.M., Delos Santos E., Chen Z., Santos O., Ayral-Kaloustian S., Brooijmans N., Mallon R., Hollander I., Feldberg L., Lucas J., Chaudhary I., Yu K., Gibbons J., Abraham R., Mansour T.S. Lead optimization of N-3-substituted 7-morpholinotriazolopyrimidines as dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors: discovery of PKI-402. J. Med. Chem. 2010, 53:798-810.
335. Mallon R., Hollander I., Feldberg L., Lucas J., Soloveva V., Venkatesan A., Dehnhardt C., Delos Santos E., Chen Z., Dos Santos O., Ayral-Kaloustian S., Gibbons J. Antitumor efficacy profile of PKI-402, a dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor. Mol. Cancer Ther. 2010, 9:976-984.
336. Rossi D.J., Ylikorkala A., Korsisaari N., Salovaara R., Luukko K., Launonen V., Henkemeyer M., Ristimaki A., Aaltonen L.A., Makela T.P. Induction of cyclooxygenase-2 in a mouse model of Peutz-Jeghers polyposis. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:12327-12332.
337. Wei C., Amos C.I., Rashid A., Sabripour M., Nations L., McGarrity T.J., Frazier M.L. Correlation of staining for LKB1 and COX-2 in hamartomatous polyps and carcinomas from patients with Peutz-Jeghers syndrome. J. Histochem. Cytochem. 2003, 51:1665-1672.
338. Udd L., Katajisto P., Rossi D.J., Lepisto A., Lahesmaa A.M., Ylikorkala A., Jarvinen H.J., Ristimaki A.P., Makela T.P. Suppression of Peutz-Jeghers polyposis by inhibition of cyclooxygenase-2. Gastroenterology 2004, 127:1030-1037.
339. Carretero J., Shimamura T., Rikova K., Jackson A.L., Wilkerson M.D., Borgman C.L., Buttarazzi M.S., Sanofsky B.A., McNamara K.L., Brandstetter K.A., Walton Z.E., Gu T.L., Silva J.C., Crosby K., Shapiro G.I., Maira S.M., Ji H., Castrillon D.H., Kim C.F., Garcia-Echeverria C., Bardeesy N., Sharpless N.E., Hayes N.D., Kim W.Y., Engelman J.A., Wong K.K. Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors. Cancer Cell 2010, 17:547-559.